Stoneridge Investment Partners LLC Sells 927 Shares of Mallinckrodt PLC (MNK)
Stoneridge Investment Partners LLC decreased its position in Mallinckrodt PLC (NYSE:MNK) by 1.1% during the second quarter, Holdings Channel reports. The firm owned 80,028 shares of the company’s stock after selling 927 shares during the period. Stoneridge Investment Partners LLC owned approximately 0.07% of Mallinckrodt PLC worth $4,864,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. Bank of Montreal Can acquired a new stake in shares of Mallinckrodt PLC during the second quarter worth $8,139,000. Oakbrook Investments LLC increased its stake in shares of Mallinckrodt PLC by 18.6% in the second quarter. Oakbrook Investments LLC now owns 7,500 shares of the company’s stock worth $456,000 after buying an additional 1,175 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its stake in shares of Mallinckrodt PLC by 55.9% in the second quarter. Robeco Institutional Asset Management B.V. now owns 8,135 shares of the company’s stock worth $495,000 after buying an additional 2,918 shares during the last quarter. Meyer Handelman Co. increased its stake in shares of Mallinckrodt PLC by 7.8% in the second quarter. Meyer Handelman Co. now owns 74,048 shares of the company’s stock worth $4,500,000 after buying an additional 5,350 shares during the last quarter. Finally, LS Investment Advisors LLC increased its stake in shares of Mallinckrodt PLC by 2.4% in the second quarter. LS Investment Advisors LLC now owns 5,408 shares of the company’s stock worth $329,000 after buying an additional 126 shares during the last quarter. Institutional investors own 94.76% of the company’s stock.
Mallinckrodt PLC (NYSE:MNK) traded down 0.93% on Monday, reaching $75.41. The company’s stock had a trading volume of 786,098 shares. The stock has a market cap of $8.12 billion, a PE ratio of 14.22 and a beta of 1.52. Mallinckrodt PLC has a 12-month low of $50.90 and a 12-month high of $85.83. The company’s 50 day moving average price is $77.05 and its 200-day moving average price is $65.57.
Mallinckrodt PLC (NYSE:MNK) last released its quarterly earnings data on Tuesday, August 2nd. The company reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.20. Mallinckrodt PLC had a return on equity of 17.78% and a net margin of 16.39%. The business earned $970.60 million during the quarter, compared to analysts’ expectations of $920.35 million. During the same quarter last year, the business posted $2.05 EPS. The business’s revenue was up .6% on a year-over-year basis. On average, equities analysts expect that Mallinckrodt PLC will post $7.69 EPS for the current year.
A number of equities research analysts have weighed in on the company. Vetr downgraded Mallinckrodt PLC from a “buy” rating to a “hold” rating and set a $83.20 target price for the company. in a report on Wednesday, August 17th. Mizuho lifted their target price on Mallinckrodt PLC from $83.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, August 3rd. Zacks Investment Research downgraded Mallinckrodt PLC from a “buy” rating to a “hold” rating in a report on Tuesday, July 12th. JPMorgan Chase & Co. set a $85.00 target price on Mallinckrodt PLC and gave the stock a “hold” rating in a report on Wednesday, August 3rd. Finally, Guggenheim reiterated a “buy” rating and issued a $98.00 target price on shares of Mallinckrodt PLC in a report on Wednesday, August 3rd. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $94.66.
About Mallinckrodt PLC
Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.
Want to see what other hedge funds are holding MNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mallinckrodt PLC (NYSE:MNK).
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.